HER2-positive brain metastases
Up to half of women with metastatic HER2-positive breast cancer develop brain metastases, because antibodies control the body but historically not the brain.
Incidence 30-50% in metastatic HER2+ disease. Local therapy (radiosurgery, surgery, whole-brain RT) was the mainstay; tucatinib (HER2CLIMB: CNS-PFS HR 0.32) and T-DXd (DESTINY-Breast12: intracranial ORR 71.7%) now provide systemic control, allowing deferral of radiation in selected patients. Neratinib and pyrotinib have modest CNS activity.
Pages like this
not linked directly; found by shared links- IdeaBrain metastases included by default in every solid-tumour trial
Shares Tucatinib, MRI, The brain: barrier and sanctuary, Trastuzumab deruxtecan.
- PersonNancy U. Lin
Shares HER2CLIMB, Tucatinib, HER2-positive breast cancer.
- IdeaTreat brain metastases as a disease with its own trials programme
Shares Tucatinib, The brain: barrier and sanctuary, SBRT / SABR (stereotactic radiotherapy), HER2-positive breast cancer.
- CompanyPuma Biotechnology
Shares Neratinib, HER2-positive breast cancer.
- TrialALINA
Shares Stop excluding brain metastases from cancer trials, Prevention trials aimed only at brain metastasis.
- IdeaMRI surveillance replaces prophylactic cranial irradiation in SCLC
Shares MRI, The brain: barrier and sanctuary, SBRT / SABR (stereotactic radiotherapy).
- TechnologyLaser interstitial thermal therapy (LITT)
Shares The blood–brain barrier & brain metastasis, MRI, The brain: barrier and sanctuary.
- TechnologyProphylactic cranial irradiation vs MRI surveillance
Shares The blood–brain barrier & brain metastasis, MRI, The brain: barrier and sanctuary, SBRT / SABR (stereotactic radiotherapy).